Literature DB >> 8580625

Chronic active Epstein-Barr virus infection in children in Japan.

S Ishihara1, S Okada, H Wakiguchi, T Kurashige, T Morishima, K Kawa-Ha.   

Abstract

The patients with chronic active Epstein-Barr virus infection (CAEBV) in childhood in Japan are described. Among 39 registered cases, 20 patients were males and 19 were females. Unlike the X-linked lymphoproliferative syndrome, there was no hereditary background. The incidence of hypersensitivity to mosquito bites was high (31.3%) as a past history. Most patients exhibited hepatomegaly (92.3%), splenomegaly (87.2%) and fever (84.6%). The incidence of absent anti-EB virus nuclear antigen titres was unexpectedly low (17.1%). Lymphoreticular disorders and cardiovascular diseases were major complications. Twenty-four (61.5%) patients died 6 months to 8 years after the onset, mainly of hepatic failure (eight cases), cardiac failure (five cases), virus-associated haemophagocytic syndrome (three cases) and haematological malignancies (two cases). This study reveals the CAEBV in Japan has several clinical features and should be informative for the pathogenesis of EB virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580625     DOI: 10.1111/j.1651-2227.1995.tb13547.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  14 in total

Review 1.  How we treat chronic active Epstein-Barr virus infection.

Authors:  Akihisa Sawada; Masami Inoue; Keisei Kawa
Journal:  Int J Hematol       Date:  2017-02-16       Impact factor: 2.490

2.  A case of hypersensitivity to mosquito bite associated with Epstein-barr viral infection and natural killer cell lymphocytosis.

Authors:  Eui Jung Roh; Eun Hee Chung; Young Pyo Chang; Na Hye Myoung; Young Koo Jee; Min Seo; Jin Han Kang
Journal:  J Korean Med Sci       Date:  2010-01-25       Impact factor: 2.153

3.  Cytotoxic chemotherapy successfully induces durable complete remission in 2 patients with mosquito allergy resulting from Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative disease.

Authors:  M Koyama; Y Takeshita; A Sakata; A Sawada; M Yasui; T Okamura; M Inoue; K Kawa
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

4.  Fatal Systemic Vasculitis Associated with Chronic Active Epstein-Barr Virus Infection.

Authors:  Oumama Jamal; Nawal Sahel; Rachida Saouab; Mohammed El Qatni; Meryem Zaizaa; Ilyas El Kassimi; Adil Rkiouak; Salaheddine Hammi; Youssef Sekkach
Journal:  Mo Med       Date:  2021 May-Jun

5.  Glomerulonephritis in a patient with chronic active Epstein-Barr virus infection.

Authors:  Kenichi Kano; Yumi Yamada; Yuhya Sato; Osamu Arisaka; Yuko Ono; Yoshihiko Ueda
Journal:  Pediatr Nephrol       Date:  2004-10-21       Impact factor: 3.651

6.  EBV Chronic Infections.

Authors:  Pizzigallo Eligio; Racciatti Delia; Gorgoretti Valeria
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-10       Impact factor: 2.576

7.  Immunologic difference between hypersensitivity to mosquito bite and hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection.

Authors:  Wen-I Lee; Jainn-Jim Lin; Meng-Ying Hsieh; Syh-Jae Lin; Tang-Her Jaing; Shih-Hsiang Chen; Iou-Jih Hung; Chao-Ping Yang; Chin-Jung Chen; Yhu-Chering Huang; Shin-Pai Li; Jing-Long Huang
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

8.  Successful Cord Blood Stem Cell Transplantation for an Adult Case of Chronic Active Epstein-Barr Virus Infection.

Authors:  Masuho Saburi; Masao Ogata; Takako Satou; Natsumi Yoshida; Kentaro Nagamatsu; Yuko Nashimoto; Yui Moroga; Kuniko Takano; Kazuhiro Kohno; Kuniaki Shirao
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

9.  Severe chronic active EBV infection in an adult patient: case report.

Authors:  Sang-Yoon Ha; Chul-Won Chung; Young H Ko
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

10.  M-protein-positive chronic active Epstein-Barr virus infection: features mimicking HIV-1 infection.

Authors:  Shinsaku Imashuku; Naoto Azuma; Hirokazu Kanegane; Yoshihito Kasahara
Journal:  Int J Hematol       Date:  2009-07-09       Impact factor: 2.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.